Target intelligence / Profile preview

Protein-protein interaction surface (PPI surface)

Target
PPI surface
Molecular classification
Other
01

Overview

Protein-protein interaction surfaces refer to the regions on proteins that mediate direct physical contacts between protein molecules, allowing for the formation of multi-protein assemblies crucial for cellular functions such as signaling, structural organization, regulation, and catalysis[1][3]. These surfaces are characterized by specific arrangements of amino acids that provide shape and chemical complementarity for binding; forces such as hydrophobic interactions, hydrogen bonding, van der Waals interactions, and electrostatic forces commonly stabilize these interfaces[6][7]. The biological consequence of PPIs depends on the proteins involved, with roles in virtually all aspects of biology, health, and disease. Modulating PPIs has become a major focus in drug discovery, but targeting these surfaces poses unique structural and pharmacological challenges due to their often large and featureless nature[8][5].

Other names
Protein-protein interfacePPI interfaceProtein-binding surface
02

Mechanism of action

Inhibition of protein–protein association, Stabilization of protein complexes, Allosteric modulation of interacting partners

03

Biological functions

Signal transductionCell cycle regulationApoptosisImmune responseCellular organizationMetabolic regulationOther
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular diseaseInfectionInflammationOther
05

Safety considerations

Specificity: Targeting protein–protein interaction surfaces can be challenging, as these surfaces are often large, flat, and less well defined than typical enzyme active sites, increasing off-target riskPotential for disrupting essential cellular networks, as many PPIs are fundamental to normal cell functionDrugability: Many PPI surfaces are technically difficult to target with small molecules due to size, topology, and lack of defined pockets
06

Interacting drugs

Several small molecules and biologics are designed to inhibit or stabilize PPIs (e.g., venetoclax for BCL-2:BAX, navitoclax, nutlin-3 for p53:MDM2), but no single drug targets the generic "PPI surface"
07

Biomarkers

None specific to generic PPI surfaces. Biomarkers relate to specific protein–protein interactions or complexes.

Beyond the preview

Go deeper on Protein-protein interaction surface (PPI surface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein-protein interaction surface (PPI surface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call